WHO ICTRP trial
A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for…
EUCTR2008-003924-52-SE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2008-003924-52-SE |
|---|---|
| Public title | A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis |
| Scientific title | A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis |
| Primary sponsor | PTC Therapeutics, Inc |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | France;Spain;Belgium;Germany;Netherlands;Italy;United Kingdom;Sweden |
| Conditions | Nonsense-Mutation-Mediated Cystic Fibrosis MedDRA version: 9.1 Level: LLT Classification code 10011762 Term: Cystic fibrosis |
| Interventions | Product Name: PTC124 Product Code: PTC124 Pharmaceutical Form: Powder for oral suspension INN or Proposed INN: ataluren CAS Number: 775304-57-9 Current Sponsor code: PTC124 Other descriptive name: PTC-0161480; PTC-124; Compound 1a; RPS… |
| Registration date | Dec 17, 2008 |
| Target size | 208 |
| Secondary IDs | PTC124-GD-009-CF |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: